Market Overview:
The global hepatitis C virus envelope protein E2 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of hepatitis C, rising demand for novel therapies, and growing investments in R&D. By type, the E-20 segment is expected to account for the largest share of the global market in 2018. By application, the hepatitis C segment is expected to account for a major share of the global market in 2018.
Product Definition:
Hepatitis C virus envelope protein E2 is a viral protein that is essential for the replication of hepatitis C virus. It is responsible for the assembly and budding of new viruses from infected cells.
E-20:
E-20 is a protein that acts as an intercellular signal peptide for the release of cytotoxic proteins. It is also involved in viral budding and probably plays a role in virus infection. The growth factor for Hepatitis C Virus (HCV) Envelope Protein E2 (EPE2) market is expected to be positive since there are no major substitutes available, and it has been observed that this product has good safety profile with minimal side effects.
MBL-HCV-1:
MB-HCV-1 is a protein that acts as an outer coat protein of the hepatitis C virus. It is also known as the envelope 2 (E2) protein or sometimes just referred to as HCV E2. MB-HCV-1 has been shown to have antiviral activity in vitro and in vivo against many viruses including HIV, SARSCoV - 2, and picornavirus 17S RNA.
Application Insights:
Based on application, the global hepatitis C virus envelope protein e2 market is segmented into hepatitis C, genital warts and others. The hepatitis C segment dominated the overall market in terms of revenue share in 2017. This high share is attributable to a large patient base that has been diagnosed with chronic liver disease due to lack of effective treatment options for HCV infection. Moreover, introduction of new drugs for the treatment of chronic HCV infection will boost growth over the forecast period.
The other applications segment includes diagnosis of infectious diseases by means viral culture and identification techniques such as immunofluorescence microscopy and enzyme-linked immunosorbent assay (ELISA). Thus, increasing incidence rate of infectious diseases will drive demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Gilead Sciences, Inc.; Merck & Co., Inc.; and AbbVie, Inc. Moreover, these companies are constantly engaged in research activities to develop novel HCV drugs with improved efficacy and safety profile. In addition, rising prevalence of hepatitis C virus (HCV) infection is also expected to fuel growth over the forecast period. For instance, according to CDC’s National Center for Health Statistics (NCHS), from 2015-2016 there were an estimated 602 thousand people living with HCV infection in U.S., which is around 4% of population aged 12 months - 64 years old at that time [1].
Growth Factors:
- Increasing prevalence of hepatitis C virus infection: The increasing prevalence of hepatitis C virus infection is the major growth driver for the hepatitis C virus envelope protein E2 market. According to World Health Organization, approximately 71 million people were infected with HCV worldwide in 2015, and around 399,000 people died due to HCV-related diseases. This number is expected to increase in the coming years owing to the increasing incidence of viral infections across the globe.
- Rising demand for novel therapies: The rising demand for novel therapies is another key growth driver for the hepatitis C virus envelope protein E2 market. Due to high unmet needs and side effects associated with existing treatments, there is a growing demand for novel therapies that can offer better cure rates and fewer side effects than currently available treatments options. This is expected to drive the growth of this market in future years.
- Growing investment in R&D activities: The growing investment in R&D activities by pharmaceutical companies is another key factor driving the growth of this market. Pharmaceutical companies are investing heavily in R&D activities aimed at developing new drugs that can offer better cure rates and fewer side effects than currently available treatment options for HCV patients.. This will help fuelthegrowthofthehepatitisCvirusenvelopeproteinE2marketinfutureyears..
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatitis C Virus Envelope Protein E2 Market Research Report
By Type
E-20, MBL-HCV-1, CIGB-230, BTA-074, Others
By Application
Hepatitis C, Genital Warts, Others
By Companies
Aviragen Therapeutics Inc, Integrated BioTherapeutics Inc, Aviragen Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Hepatitis C Virus Envelope Protein E2 Market Report Segments:
The global Hepatitis C Virus Envelope Protein E2 market is segmented on the basis of:
Types
E-20, MBL-HCV-1, CIGB-230, BTA-074, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis C, Genital Warts, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aviragen Therapeutics Inc
- Integrated BioTherapeutics Inc
- Aviragen Therapeutics Inc
Highlights of The Hepatitis C Virus Envelope Protein E2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- E-20
- MBL-HCV-1
- CIGB-230
- BTA-074
- Others
- By Application:
- Hepatitis C
- Genital Warts
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatitis C Virus Envelope Protein E2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hepatitis C Virus Envelope Protein E2 is a protein that helps the virus attach to cells.
Some of the major companies in the hepatitis c virus envelope protein e2 market are Aviragen Therapeutics Inc, Integrated BioTherapeutics Inc, Aviragen Therapeutics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hepatitis C Virus Envelope Protein E2 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hepatitis C Virus Envelope Protein E2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hepatitis C Virus Envelope Protein E2 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hepatitis C Virus Envelope Protein E2 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hepatitis C Virus Envelope Protein E2 Market Size & Forecast, 2020-2028
4.5.1 Hepatitis C Virus Envelope Protein E2 Market Size and Y-o-Y Growth
4.5.2 Hepatitis C Virus Envelope Protein E2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 E-20
5.2.2 MBL-HCV-1
5.2.3 CIGB-230
5.2.4 BTA-074
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hepatitis C
6.2.2 Genital Warts
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hepatitis C Virus Envelope Protein E2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hepatitis C Virus Envelope Protein E2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 E-20
9.6.2 MBL-HCV-1
9.6.3 CIGB-230
9.6.4 BTA-074
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hepatitis C
9.10.2 Genital Warts
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 E-20
10.6.2 MBL-HCV-1
10.6.3 CIGB-230
10.6.4 BTA-074
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hepatitis C
10.10.2 Genital Warts
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 E-20
11.6.2 MBL-HCV-1
11.6.3 CIGB-230
11.6.4 BTA-074
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hepatitis C
11.10.2 Genital Warts
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 E-20
12.6.2 MBL-HCV-1
12.6.3 CIGB-230
12.6.4 BTA-074
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hepatitis C
12.10.2 Genital Warts
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 E-20
13.6.2 MBL-HCV-1
13.6.3 CIGB-230
13.6.4 BTA-074
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hepatitis C
13.10.2 Genital Warts
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hepatitis C Virus Envelope Protein E2 Market: Competitive Dashboard
14.2 Global Hepatitis C Virus Envelope Protein E2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aviragen Therapeutics Inc
14.3.2 Integrated BioTherapeutics Inc
14.3.3 Aviragen Therapeutics Inc
